Skip to main content
Log in

Valsartan/Hydrochlorothiazide

A Viewpoint by Henry R. Black

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multi-dose, double-blind, placebo-controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861–6

    Article  PubMed  CAS  Google Scholar 

  2. Black HR, Graff A, Glazer R, et al. Valsartan in combination with hydrochlorothiazide: dose responsive efficacy reduces incidence of diuretic-induced hypokalemia. Presented at the International Forum on Angiotensin II Receptor Antagonism, Monte Carlo ’99 All, Monte Carlo, 27–30 Jan 1999

  3. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62

    Article  PubMed  CAS  Google Scholar 

  4. Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–46

    Google Scholar 

  5. Black HR. Fixed-dose combination therapy for hypertension. Patient Care 1997 May; 13–20

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Black, H.R. Valsartan/Hydrochlorothiazide. Drugs 57, 757 (1999). https://doi.org/10.2165/00003495-199957050-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199957050-00011

Navigation